SubHero Banner
Text

Erleada® (apalutamide) – New indication

September 17, 2019 - Janssen announced the FDA approval of Erleada (apalutamide), for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Download PDF